Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study
DOI:
https://doi.org/10.2340/00015555-3712Keywords:
anxiety, depression, psoriasis, secukinumab, quality of lifeAbstract
This study evaluated whether secukinumab treatment for patients with moderate to severe plaque psoriasis correlates with improvements in symptoms of anxiety and depression. SUPREME was a 24-week, phase IIIb, multicentre, prospective study conducted across 50 centres in Italy with an extension period of up to 72 weeks. Assessments used were: Psoriasis Area Severity Index (PASI), Hospital Anxiety and Depression Scale (HADS) – Anxiety (HADS-A), and HADS – Depression (HADS-D) scores and Dermatology Quality Life Index (DLQI). Compared with baseline, a significantly greater proportion of patients who reported moderate to severe clinical symptoms of anxiety or depression (HADS-A or HADS-D ≥ 11) were free of moderate to severe symptoms at weeks 16 and 48. The PASI and DLQI scores reduced over time with secukinumab treatment. Psoriasis treatment with secukinumab for 48 weeks resulted in significantly improved skin clearance and a parallel improvement in symptoms of anxiety and depression, assessed by HADS.
Downloads
References
Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
DOI: https://doi.org/10.1016/S0140-6736(07)61128-3
Menter A. Psoriasis and psoriatic arthritis overview. Am J Manag Care 2016; 22: s216-224.
Kimball AB, Leonardi C, Stahle M, Gulliver W, Chevrier M, Fakharzadeh S, et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol 2014; 171: 137-147.
DOI: https://doi.org/10.1111/bjd.13013
Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146: 891-895.
DOI: https://doi.org/10.1001/archdermatol.2010.186
Wu JJ, Feldman SR, Koo J, Marangell LB. Epidemiology of mental health comorbidity in psoriasis. J Dermatolog Treat 2018; 29: 487-495.
DOI: https://doi.org/10.1080/09546634.2017.1395800
Lakuta P, Przybyla-Basista H. Toward a better understanding of social anxiety and depression in psoriasis patients: the role of determinants, mediators, and moderators. J Psychosom Res 2017; 94: 32-38.
DOI: https://doi.org/10.1016/j.jpsychores.2017.01.007
Nazik H, Nazik S, Gul FC. Body image, self-esteem, and quality of life in patients with psoriasis. Indian Dermatol Online J 2017; 8: 343-346.
DOI: https://doi.org/10.4103/idoj.IDOJ_503_15
Armstrong AW, Vender R, Kircik L. Secukinumab in the treatment of palmoplantar, nail, scalp, and pustular psoriasis. J Clin Aesthet Dermatol 2016; 9: S12-s16.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis - results of two phase 3 trials. N Engl J Med 2014; 371: 326-338.
DOI: https://doi.org/10.1056/NEJMoa1314258
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med 2015; 373: 2534-2548.
DOI: https://doi.org/10.1056/NEJMoa1505066
Thaci D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015; 73: 400-409.
DOI: https://doi.org/10.1016/j.jaad.2015.05.013
Zeichner JA, Armstrong A. The role of IL-17 in the pathogenesis and treatment of psoriasis. J Clin Aesthet Dermatol 2016; 9: S3-S6.
Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol 2017; 77: 667-674.
DOI: https://doi.org/10.1016/j.jaad.2017.05.033
Bissonnette R, Luger T, Thaci D, Toth D, Lacombe A, Xia S, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol 2018; 32: 1507-1514.
DOI: https://doi.org/10.1111/jdv.14878
Gottlieb A, Sullivan J, van Doorn M, Kubanov A, You R, Parneix A, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol 2017; 76: 70-80.
DOI: https://doi.org/10.1016/j.jaad.2016.07.058
Reich K, Sullivan J, Arenberger P, Mrowietz U, Jazayeri S, Augustin M, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol 2018; 181: 954-966.
DOI: https://doi.org/10.1111/bjd.17351
Thaci D, Puig L, Reich K, Tsai TF, Tyring S, Kingo K, et al. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: results from the CLEAR study. J Am Acad Dermatol 2019; 81: 1405-1409.
DOI: https://doi.org/10.1016/j.jaad.2019.04.045
Costanzo A, Bianchi L, Flori ML, Malara G, Stingeni L, Bartezaghi M, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol 2018; 179: 1072-1080.
DOI: https://doi.org/10.1111/bjd.16705
Snaith RP. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes 2003; 1: 29.
DOI: https://doi.org/10.1186/1477-7525-1-29
Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361-370.
DOI: https://doi.org/10.1111/j.1600-0447.1983.tb09716.x
Papini M, Cusano F, Romanelli M, Burlando M, Stinco G, Girolomoni G, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study. Br J Dermatol 2019; 181: 413-414.
DOI: https://doi.org/10.1111/bjd.18013
Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat 2003; 14: 158-165.
DOI: https://doi.org/10.1080/09546630310013360
Singer S, Danker H, Dietz A, Hornemann B, Koscielny S, Oeken J, et al. Screening for mental disorders in laryngeal cancer patients: a comparison of 6 methods. Psychooncology 2008; 17: 280-286.
DOI: https://doi.org/10.1002/pon.1229
Almawi W, Tamim H, Al-Sayed N, Arekat MR, Al-Khateeb GM, Baqer A, et al. Association of comorbid depression, anxiety, and stress disorders with Type 2 diabetes in Bahrain, a country with a very high prevalence of Type 2 diabetes. J Endocrinol Invest 2008; 31: 1020-1024.
DOI: https://doi.org/10.1007/BF03345642
Pelle AJM, Gidron YY, Szabó BM, Denollet J. Psychological predictors of prognosis in chronic heart failure. J Card Fail 2008; 14: 341-350.
DOI: https://doi.org/10.1016/j.cardfail.2008.01.004
Tsang A, Von Korff M, Lee S, Alonso J, Karam E, Angermeyer MC, et al. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain 2008; 9: 883-891.
DOI: https://doi.org/10.1016/j.jpain.2008.05.005
Golpour M, Hosseini SH, Khademloo M, Ghasemi M, Ebadi A, Koohkan F, et al. Depression and anxiety disorders among patients with psoriasis: a hospital-based case-control study. Dermatol Res Pract 2012; 2012: 381905-381905.
DOI: https://doi.org/10.1155/2012/381905
Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, et al. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol 2018; 32: 1940-1949.
DOI: https://doi.org/10.1111/jdv.15012
Reich K, Foley P, Han C, McElligott S, Muser E, Li N, et al. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. J Dermatolog Treat 2020; 31: 617-623.
DOI: https://doi.org/10.1080/09546634.2019.1628172
Elgendi A, Nada H, Mosbeh AS, Maatouk M, Abulghany M, Gulliver W. Depression over psoriasis: assessment of associated relief by addition of adalimumab for the treatment of psoriasis: observational study (DORADO - Ps). Journal of Dermatology & Dermatologic Surgery 2015; 19: 15-20.
DOI: https://doi.org/10.1016/j.jdds.2014.03.005
Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, et al. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. J Eur Acad Dermatol Venereol 2015; 29: 1063-1070.
DOI: https://doi.org/10.1111/jdv.12909
Lamb RC, Matcham F, Turner MA, Rayner L, Simpson A, Hotopf M, et al. Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting. Br J Dermatol 2017; 176: 1028-1034.
DOI: https://doi.org/10.1111/bjd.14833
Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010; 63: 457-465.
DOI: https://doi.org/10.1016/j.jaad.2009.09.014
Strober B, Gooderham M, de Jong E, Kimball AB, Langley RG, Lakdawala N, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol 2018; 78: 70-80.
DOI: https://doi.org/10.1016/j.jaad.2017.08.051
Yang A, Xin X, Yang W, Li M, Yang W, Li L, et al. L'étanercept réduit l'anxiété et la dépression chez les patients atteints de psoriasis, et la dépression chronique est corrélée à la réduction de la réponse à l'étanercept. Ann Dermatol Venereol 2019; 146: 363-371.
DOI: https://doi.org/10.1016/j.annder.2019.03.002
Griffiths CEM, Fava M, Miller AH, Russell J, Ball SG, Xu W, et al. Impact of ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate-to-severe psoriasis: an integrated analysis of three phase 3 clinical studies. Psychother Psychosom 2017; 86: 260-267.
DOI: https://doi.org/10.1159/000479163
Tribó MJ, Turroja M, Castaño-Vinyals G, Bulbena A, Ros E, García-Martínez P, et al. Patients with moderate to severe psoriasis associate with higher risk of depression and anxiety symptoms: results of a multivariate study of 300 Spanish individuals with psoriasis. Acta Derm Venereol 2019; 99: 417-422.
DOI: https://doi.org/10.2340/00015555-3114
McDonough E, Ayearst R, Eder L, Chandran V, Rosen CF, Thavaneswaran A, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol 2014; 41: 887-896.
DOI: https://doi.org/10.3899/jrheum.130797
Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol 2018; 178: 854-862.
DOI: https://doi.org/10.1111/bjd.16083
Mabuchi T, Ota T, Manabe Y, Ikoma N, Ozawa A, Terui T, et al. HLA-C*12:02 is a susceptibility factor in late-onset type of psoriasis in Japanese. J Dermatol 2014; 41: 697-704.
DOI: https://doi.org/10.1111/1346-8138.12569
Nair RP, Stuart P, Henseler T, Jenisch S, Chia NV, Westphal E, et al. Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet 2000; 66: 1833-1844.
DOI: https://doi.org/10.1086/302932
Gudjónsson JE, Kárason A, Antonsdóttir AA, Rúnarsdóttir EH, Gulcher JR, Stefánsson K, et al. HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol 2002; 118: 362-365.
DOI: https://doi.org/10.1046/j.0022-202x.2001.01656.x
Jin Y, Yang S, Zhang F, Kong Y, Xiao F, Hou Y, et al. Combined effects of HLA-Cw6 and cigarette smoking in psoriasis vulgaris: a hospital-based case-control study in China. J Eur Acad Dermatol Venereol 2009; 23: 132-137.
DOI: https://doi.org/10.1111/j.1468-3083.2008.02951.x
Strober BE, Langley RGB, Menter A, Magid M, Porter B, Fox T, et al. No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis. Br J Dermatol 2018; 178: e105-e107.
DOI: https://doi.org/10.1111/bjd.16051
Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Therapy 2019; 21: 111.
DOI: https://doi.org/10.1186/s13075-019-1882-2
van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol 2016; 75: 83-98.e84.
DOI: https://doi.org/10.1016/j.jaad.2016.03.024
Danesh MJ, Kimball AB. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. J Am Acad Dermatol 2016; 74: 190-192.
DOI: https://doi.org/10.1016/j.jaad.2015.08.057
Gooderham M, Gavino-Velasco J, Clifford C, MacPherson A, Krasnoshtein F, Papp K. A review of psoriasis, therapies, and suicide. J Cutan Med Surg 2016; 20: 293-303.
DOI: https://doi.org/10.1177/1203475416648323
Siliq prescribing information. (last accessed on 12 Dec 2019) Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf.
Kyntheum Assessment Report. Available at: https://www.ema.europa.eu/en/documents/assessment-report/kyntheum-epar-public-assessment-report.
Published
How to Cite
License
Copyright (c) 2021 Marina Talamonti, Giovanna Malara, Ylenia Natalini, Federico Bardazzi, Andrea Conti, Andrea Chiricozzi, Cristina Mugheddu, Paolo Gisondi, Stefano Piaserico, Gianluca Pagnanelli, Paolo Amerio, Concetta Potenza, Franca Cantoresi, Maria Concetta Fargnoli, Anna Balato, Francesco Loconsole, Annamaria Offidani, Claudio Bonifati, Francesca Prignano, Marta Bartezaghi, Alice Rausa, Elisabetta Aloisi, Roberto Orsenigo, Antonio Costanzo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
